Predicting the curative effects of TPD chemotherapy for HER2-positive breast cancer using tumor-infiltrating lymphocytes

被引：0
|
作者：
Kashiwagi, Shinichiro [1 ]
Goto, Wataru [1 ]
Asano, Yuka [1 ]
Takashima, Tsutomu [1 ]
Onoda, Naoyoshi [1 ]
Hirakawa, Kosei [1 ]
Ohira, Masaichi [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1 - 8 - 2
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
    Xia Yang
    Jia Rao
    Wentao Yang
    Ruohong Shui
    Targeted Oncology, 2018, 13 : 757 - 767
  • [22] The Dual Role of Tumor-Infiltrating Lymphocytes in HER2-Positive Primary Breast Cancer Two Sides of the Same Coin?
    Loibl, Sibylle
    JAMA ONCOLOGY, 2015, 1 (04) : 455 - 456
  • [23] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
    Fasani, R.
    Comerma, L.
    Pagliuca, F.
    Thyparambil, S.
    Peg, V.
    Jimenez, J.
    Cecchi, F.
    Hembrough, T.
    Perez, J.
    Arribas, J.
    Cortes, J.
    Scaltriti, M.
    Saura, C.
    Nuciforo, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S128 - S128
  • [25] Tumor-Infiltrating Lymphocytes in HER2-Low Breast Cancer
    Fernandes, Italo
    Scorsato, Anderson
    Kaliks, Rafael
    Corpa, Marcus
    Damasceno, Eduarda
    Schvartsman, Gustavo
    CLINICAL BREAST CANCER, 2023, 23 (07) : e470 - e479
  • [26] Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer
    Kotoula, V.
    Giannoulatou, E.
    Kouvatseas, G.
    Tikas, I.
    Lazaridis, G.
    Charalambous, E.
    Efstratiou, I.
    Bobos, M.
    Tsolaki, E.
    Zagouri, F.
    Christodoulou, C.
    Pentheroudakis, G.
    Koutras, A.
    Papakostas, P.
    Kosmidis, P. A.
    Pectasides, D.
    Fountzilas, G.
    CANCER RESEARCH, 2017, 77
  • [27] Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
    Lee, Hee Jin
    Kim, Joo Young
    Park, In Ah
    Song, In Hye
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (02) : 278 - 288
  • [28] Tumor-infiltrating lymphocytes evaluation using machine learning image analysis based on core needle biopsy in HER2-positive breast cancer
    Abe, Norie
    Matsumoto, Hirofumi
    Takamatsu, Reika
    Tamaki, Kentaro
    Takigami, Naoko
    Uehara, Kanou
    Kamada, Yoshihiko
    Tamaki, Nobumitsu
    Motonari, Tokiwa
    Nakada, Norihiro
    Zaha, Hisamitsu
    Yoshimi, Naoki
    CANCER RESEARCH, 2020, 80 (04)
  • [29] The predictive value of tumor-infiltrating lymphocytes and PD-L1 expression on the efficacy of neoadjuvant trastuzumab plus chemotherapy in HER2-positive breast cancer
    Li, Huihui
    Shang, Mao
    Chi, Yajing
    Yin, Sha
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer
    Robertson, Stephanie
    Ronnlund, Caroline
    Fredriksson, Irma
    Foukakis, Theodoros
    Hartman, Johan
    CANCER RESEARCH, 2022, 82 (04)
12345